You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Atezolizumab

Showing 576 - 600 of 765
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS Trial in United States (Atezolizumab, Azacitidine)

Completed
  • Myelodysplastic Syndromes
  • Duarte, California
  • +14 more
Aug 15, 2019

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in United States (Crizotinib, Palbociclib, Sunitinib)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • Birmingham, Alabama
  • +125 more
Nov 21, 2022

SCLC, Extensive Stage Trial in Zhengzhou (Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive

Not yet recruiting
  • SCLC, Extensive Stage
  • Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
  • (no location specified)
Aug 2, 2021

Colorectal Cancer Trial in Spain, United States (Atezolizumab, Bevacizumab, Cobimetinib)

Completed
  • Colorectal Cancer
  • Atezolizumab
  • +2 more
  • Aurora, Colorado
  • +5 more
Aug 9, 2019

Efficacy, Safety Trial (PD-L1 inhibitor)

Not yet recruiting
  • Efficacy
  • Safety
  • PD-L1 inhibitor
  • (no location specified)
Apr 6, 2022

Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III Trial in Boston (Implantable Microdevice (IMD))

Not yet recruiting
  • Triple Negative Breast Cancer
  • +6 more
  • Implantable Microdevice (IMD)
  • Boston, Massachusetts
  • +1 more
Mar 8, 2023

Tumors Trial in Cangzhou (oncolytic virus (OVV-01) injection)

Recruiting
  • Neoplasms
  • oncolytic virus (OVV-01) injection
  • Cangzhou, HE BEI, China
    North China Petroleum Bureau General Hospital
Jul 1, 2021

Patients With Stage 0-IV Melanoma in Real Clinical Practice

Recruiting
  • Melanoma
  • +7 more
  • surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
  • Moscow, Russian Federation
    N.N. Blokhin Russian Cancer Research Center
Jun 12, 2022

Study of Adverse Renal Effects of Immune Checkpoints Inhibitors

Completed
  • Adverse Effect
  • Renal Toxicity
  • Renal Tolerance to Immunotherapy
  • Pierre-Bénite, France
    Department of Nephrology, Centre Hospitalier Lyon Sud, Hospices
Aug 12, 2019

Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer Trial in Sydney, Hong Kong (ARB202)

Recruiting
  • Gastrointestinal Cancer
  • +5 more
  • Adelaide, Australia
  • +3 more
Dec 13, 2022

Colorectal Cancer Trial in Worldwide (Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib)

Completed
Has Results
  • Colorectal Cancer
  • Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
  • +2 more
  • Duarte, California
  • +72 more
Dec 3, 2019

Cancer, Immune-related Adverse Event Trial in Durham (Medical chart review)

Enrolling by invitation
  • Cancer
  • Immune-related Adverse Event
  • Medical chart review
  • Durham, North Carolina
    Duke University Medical Center
Oct 20, 2023

Non-small-cell Lung Cancer Patients Trial in Italy (Atezolizumab, Bevacizumab)

Not yet recruiting
  • Non-small-cell Lung Cancer Patients
  • Ancona, Italy
  • +15 more
Mar 28, 2019

Urothelial Carcinoma Trial in Worldwide (MOXR0916, Atezolizumab)

Terminated
Has Results
  • Urothelial Carcinoma
  • Tucson, Arizona
  • +21 more
May 30, 2019

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant

Not yet recruiting
  • BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
  • Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
  • Bobigny, France
    Hospitl Avicenne
Sep 13, 2023

PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging

Completed
  • Non-small Cell Lung Cancer (NSCLC)
    • Nîmes, France
      Jean-Paul BEREGI
    Jan 25, 2023

    Hepatocellular Carcinoma Trial (SynOV1.1, Atezolizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • SynOV1.1
    • Changchun, Jilin, China
      The First Hospital of Jilin University
    Jan 31, 2023

    EXploring Immune-related Adverse Events of Immune checkpoinT

    Active, not recruiting
    • Cancer
    • +2 more
    • Immune checkpoint inhibitor
    • Paris, France
    • +1 more
    Jul 5, 2023

    HCC Trial in Hong Kong (Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib)

    Not yet recruiting
    • HCC
    • Zabadinostat (CXD101) and Geptanolimab
    • Lenvatinib and Sorafenib
    • Hong Kong, Hong Kong
      Department of Clinical Oncology, Prince of Wales Hospital
    May 15, 2023

    NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation Trial in Hong Kong (Atezolizumab, Bevacizumab, Carboplatin)

    Unknown status
    • NSCLC Stage IIIB
    • +2 more
    • Atezolizumab
    • +3 more
    • Hong Kong, Hong Kong
      Department of Clinical Oncology
    Apr 16, 2019

    Renal Cell Carcinoma Trial in Worldwide (Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib)

    Completed
    Has Results
    • Renal Cell Carcinoma
    • Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
    • +2 more
    • Scottsdale, Arizona
    • +44 more
    Dec 19, 2019

    EvaluatioN of durvALumab Utilization and Effectiveness for First

    Recruiting
    • Small Cell Lung Carcinoma
    • Angers, France
    • +24 more
    Jan 12, 2023

    HER2-positive Breast Cancer Trial in Seoul (TAHP and AHP, TAHP plus AC and AHP)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • TAHP and AHP
    • TAHP plus AC and AHP
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Mar 19, 2019

    Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

    Recruiting
    • Immunotherapy
    • Second-line Treatment
    • Guizhou, ZunYi, China
      The Second Affiliated Hospital of Zunyi Medical University
    Jun 14, 2023

    Adjuvant Immune Checkpoint Inhibitors in Postoperative

    Recruiting
    • Hepatocellular Carcinoma
    • Immune Checkpoint Inhibitors Based Adjuvant therapy
    • Nanning, Guangxi, China
      Jian-Hong Zhong
    Jan 18, 2023